NCT00210769View on ClinicalTrials.gov

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

December 31, 2005

Conditions
Schizophrenia
Interventions
DRUG

paliperidone ER Oros

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00210769 - A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia | Biotech Hunter | Biotech Hunter